Drugs / CD7-specific CAR gene-engineered T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04033302 | Jun 2026 → Dec 2029 expected | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma, acute myeloid leukemia | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD7-specific CAR gene-engineered T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04033302 ↗ |
| Modality | Cell therapy | “The engineered T cells will be applied to patients through intravenous delivery.” NCT04033302 ↗ |
| Route | Intravenous | “intravenous delivery” NCT04033302 ↗ |
| Target | CD7 | “to recognize CD7 expressed on the surface of the cancer cells” NCT04033302 ↗ |